Evotec
EVO | NASDAQ
$1.56
-$0.02 (-1.27%)
At close: Nov 16, 2026, 4:00 PM ET
$1.56
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Evotec Company Profile
Company profile explainedCompany Profile
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
Key Executives
| Name | Position |
|---|---|
| Christian Wojczewski | CEO & Chairperson of the Management Board |
| Aurelie Dalbiez | Chief People Officer & Member of Management Board |
| Claire Hinshelwood | Chief Financial Officer & Member of Management Board |
| Ingrid Mller | Chief Operating Officer & Member of Management Board |
| Christian Dargel | EVice President Global Head of Legal & Compliance |
| Christiane Honisch | SVP Head of Diagnostics |
| Cord Dohrmann | Chief Scientific Officer & Member of Management Board |
| David Hallet | Executive Vice President |
| Ian Hunneyball | Senior Vice President of Programme Management & Clinical Operations |
| Sarah Fakih | Executive VP, Head of Global Communications & Investor Relations |
| Uwe Andag | EVP Head of Metabolic Diseases |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 15, 2026 | 6-K | Filing |
| Oct 14, 2026 | SC 13D/A | [Amend] Filing |
| Oct 14, 2026 | 6-K | Filing |
| Sep 29, 2026 | 6-K | Filing |
| Sep 09, 2026 | 6-K | Filing |
| Aug 13, 2026 | 6-K | Filing |
| Jul 14, 2026 | 6-K | Filing |
| Jun 30, 2026 | 6-K | Filing |
| Jun 17, 2026 | 6-K | Filing |
| May 06, 2026 | 6-K | Filing |
Evotec
| Country | Germany |
| IPO Date | Feb 5, 2004 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 4,553 |
| CEO | Christian Wojczewski |
Stock Details
| Ticker Symbol | EVO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001412558 |
| CUSIP Number | 30050E105 |
| ISIN Number | US30050E1055 |
| SIC Code | 2834 |
Recent News
- 8 months ago / seekingalpha.comEvotec SE (EVO) Discusses Horizon Initiative as Next Phase in Strategic Transformation for Operational Excellence and Growth Transcript
- 9 months ago / newsfilecorp.comMoving iMage Transforms Eight Screen Santa Fe Theater Complex for EVO Entertainment with Cutting-Edge Laser Projection and Digital Sound Systems, including an EVX Enhanced Viewing Experience Auditorium
- 9 months ago / businesswire.comFDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction
- 9 months ago / businesswire.comEvommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
Add to Watchlist
Select watchlists to add or remove EVO